GELS vs IMRN
Gelteq Ltd. and Immuron Ltd., side by side — 2 fiscal years reported in AUD, drawn from SEC filings.
Most recent reported year
| Metric | GELS | IMRN |
|---|---|---|
| Revenue | AUD 165,645 | AUD 7.3M |
| Net income | $-6.6M | AUD -5.2M |
| Gross margin | 30.3% | 65.4% |
| Net margin | · | −71.6% |
| Return on equity | −43.0% | −50.2% |
| Diluted EPS | −AUD 0.72 | −AUD 2.26 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | AUD -5.5M | · |
| Equity | · | · |
| Net debt / equity | 0.25× | · |
| Current ratio | 0.27× | 5.09× |
| Revenue CAGR 5y | · | 23.7% |
| Profit CAGR 5y | · | · |
IMRN bills 44.0× the revenue of GELS, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
2 years side by side
| Fiscal year | GELS | IMRN |
|---|---|---|
| FY2024 | AUD 165,645 | AUD 7.3M |
| FY2022 | AUD 79,843 | AUD 1.8M |
Bottom line
| Fiscal year | GELS | IMRN |
|---|---|---|
| FY2024 | $-6.6M | AUD -5.2M |
| FY2022 | · | AUD -3.8M |
Standard deviation, each side
IMRN's return on equity has been more volatile than GELS's over the 3 comparable fiscal years — 13.9 percentage points of standard deviation against 10.9.
3 of 9 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between GELS and IMRN over these 3 fiscal years — GELS led in 2 and IMRN in 1.
3 of 9 comparable fiscal years — a year missing data on either side is not counted.